Position history for UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in 4D MOLECULAR THERAPEUTICS IN
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds 691 shares of FDMT (4D MOLECULAR THERAPEUTICS IN), worth $6,433 as of 2026-Q1. This is a new position.
Current Value
$6,433
Current Shares
691
Total Value Change
-$993,782
Total Shares Change
-46,961
Other major holders of FDMT: VIKING GLOBAL INVESTORS LP, RA CAPITAL MANAGEMENT, L.P., BlackRock Finance, Inc.
New |
| 691 |
- |
| $6,433 |
| 0.0% |
| $8.46 |
24 |
| 2025-Q1 | Exited | 0 | -100.0% | $0 | 0.0% | $3.63 | 0 |
| 2024-Q4 | Increased | 44,324 | +7.1% | $246,884 | 0.0% | $5.30 | 25 |
| 2024-Q3 | Decreased | 41,399 | -13.1% | $447,523 | 0.0% | $10.83 | 0 |
| 2024-Q2 | Increased | 47,652 | +48.5% | $1M | 0.0% | $20.99 | 34 |